EMEA-002480-PIP01-18
Key facts
| Active substance |
Tislelizumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0142/2019
|
| PIP number |
EMEA-002480-PIP01-18
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (excluding central nervous system, haematopoietic and lymphoid tissue neoplasms)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|